STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a…
Category: STAT+
STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus…
STAT+: Eli Lilly, riding a hot streak, expects to double planned employment in Boston research center
Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the…
STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer
MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients…
Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients
Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…
STAT+: How biotech deal-making really works behind the scenes, according to founders
What does it feel like to run a biotech startup and then get “the call”…
STAT+: After a lull, the pace of FDA authorization of AI-enabled medical devices is rising
The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools…
STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a…
.jpg)
STAT+: HHS leader on health and climate change talks health sector emissions and heat emergencies
Renee Salas, an emergency medicine physician at Massachusetts General Hospital, blames climate change for the…
STAT+: House committee hearing kicks off potential doctor pay reforms in Medicare
WASHINGTON — The House Energy & Commerce health subcommittee kicked off its first hearing in…
STAT+: The future of Biogen: Pragmatism, ‘a few moonshots,’ and no Twinkies
Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher…
STAT+: Zuckerberg and Chan on track to put $50 billion toward science: ‘That’s the trajectory we’re on’
Mark Zuckerberg and Priscilla Chan sit atop a fortune that is currently valued at $113…
STAT+: Actually, hospital price transparency does save money, advocate highlights
BOSTON — For all those who think hospital price transparency will not save money, Cynthia…
STAT+: Startup Laronde merges with another biotech in wake of data integrity issue
RNA medicines startup Laronde is merging with another startup in the wake of a scientific…
STAT+: Beam Therapeutics to lay off 20% of its staff, reevaluate programs as it cuts costs
Beam Therapeutics said Monday morning it would lay off 20% of its staff — or…
STAT+: Pharmalittle: Pfizer prices Paxlovid at $1,400 for a five-day course; EMA warns of counterfeit Ozempic
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: A 50-year battle over one additive highlights FDA’s challenges with food safety
WASHINGTON — Richard Nixon was the president when the Food and Drug Administration issued its…
STAT+: What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer
Europe’s major cancer research conference kicks off in Madrid on Friday, with headline — and…
STAT+: Dana-Farber executive says split from Mass General will benefit patients
Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery…
STAT+: Senate Finance targets Medicare Advantage brokers
Senate Finance Committee members from both parties took aim today at insurance brokers that sell…
STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs
During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but…
STAT+: NIH confirmation hearing highlights just how divisive the agency’s portfolio has become
Monica Bertagnolli, President Biden’s nominee to lead the National Institutes of Health, spent her confirmation…
STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups…
STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
STAT+: In an unusual arrangement, UnitedHealth’s board chair also owns a personal investment firm
Stephen Hemsley, the former CEO of UnitedHealth Group and its current board chair, also owns…
Opinion: STAT+: Preventive drugs may be the best solution to the antibiotic resistance crisis
The antibiotics crisis is a silent pandemic that threatens to knock modern society back into…
STAT+: Revenue cycle management company Waystar files for IPO
Revenue cycle management company Waystar filed for an initial public offering Monday with the Securities…
STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials
The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease….
STAT+: When Medicare paid doctors differently, fewer patients had heart problems
WASHINGTON — Doctors lowered the incidence of heart disease and strokes among their patients when…
STAT+: Pharmalittle: People with obesity harmed by exclusion from studies; Teva sues Colorado over ‘unconstitutional’ program
Rise and shine, everyone, another busy day is on the way. We can tell, in…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
STAT+: White House moves closer to a ban on menthol cigarettes, amid intensifying opposition from tobacco companies
WASHINGTON — The White House is about to feel what it’s like to go up…
STAT+: Teva sues Colorado over ‘unconstitutional’ program to lower cost of epinephrine injectors
In the latest tussle over the cost of medicines, Teva Pharmaceuticals has filed a lawsuit…
STAT+: Pharmalittle: Rite Aid files for bankruptcy; Alzheimer’s brain scans get broader Medicare coverage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cell and gene therapy CEOs share survival strategies amid biotech slump
CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a…
STAT+: FDA’s warning to J&J’s Abiomed signals a crackdown on digital health tools
The Food and Drug Administration is following through on its promise to regulate more health…
STAT+: Dana-Farber’s divorce from Brigham is the culmination of decades of change
On the Southeast Expressway, at the edge of the city, two billboards advertising cancer care…
STAT+: What to know about this year’s Medicare open enrollment period
It’s the middle of October — the time of year that’s filled with pumpkin spice…
STAT+: Eye docs urge Medicare to lower insurance hurdles amid shortage of repackaged Avastin
Due to a shortage of a widely used compounded medicine for serious eye diseases, two…
STAT+: UnitedHealth’s profit jumps as medical costs come in lower than expected
UnitedHealth Group has made it clear that more people, especially older adults, are seeing their…
STAT+: HHS dispatches millions to next-generation Covid targets, including intranasal vaccine
WASHINGTON — The Biden administration announced Friday that it is investing in three potential vaccines…
STAT+: Medicare to cover more brain scans related to Alzheimer’s drugs
Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque…
STAT+: Amgen reports first clinical data on new targeted cancer therapy
It’s been a busy week for a cancer drug target called PRMT5 that may play…
STAT+: Pharmalittle: Makers of toxic cough syrups face new actions; Cassava suffers new blow over Alzheimer’s drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: European regulators once again recommend Amylyx’s ALS drug be rejected
LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx…